Trial Profile
An observational follow-up study of denosumab in postmenopausal women who successfully completed eight years of the parent and extension study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Nov 2017
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 01 Nov 2017 New trial record